Afficher la notice abrégée

Immunotherapy in Hepatocellular Carcinoma

dc.contributor.editorNishida, Naoshi
dc.contributor.editorKudo, Masatoshi
dc.date.accessioned2023-05-11T17:17:06Z
dc.date.available2023-05-11T17:17:06Z
dc.date.issued2023
dc.identifierONIX_20230511_9783036566917_39
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/100022
dc.description.abstractBased on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of the art in the immunotherapy of HCC from both the basic and clinical perspectives, and outline future perspectives for improving therapies.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.classificationthema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncologyen_US
dc.subject.othercancer immunotherapy
dc.subject.otherTCGA
dc.subject.othermutations
dc.subject.othercopy number variations
dc.subject.othermicroRNAs
dc.subject.otherPD-1
dc.subject.otherPD-L1
dc.subject.otherhepatocellular carcinoma
dc.subject.otherpredictive factors
dc.subject.otherimmunotherapy
dc.subject.otherimmune checkpoint inhibition
dc.subject.othercheck-point inhibitors
dc.subject.otherliver disease
dc.subject.otheroutcome
dc.subject.otherbiomarkers
dc.subject.othercombination immunotherapy
dc.subject.otherimmune-related adverse events (irAEs)
dc.subject.otherhepatocellular carcinoma (HCC)
dc.subject.otheralpha fetoprotein response
dc.subject.otherimmune checkpoint inhibitor
dc.subject.otherunresectable hepatocellular carcinoma
dc.subject.othera disintegrin and metalloprotease 9
dc.subject.othernivolumab
dc.subject.othernatural killer
dc.subject.otherCTLA-4
dc.subject.othercombination therapy
dc.subject.otherPD-1 antibody
dc.subject.otherPD-L1 antibody
dc.subject.otheranti-VEGF inhibitor
dc.subject.othermolecular classification
dc.subject.otherimmune phenotype
dc.subject.otherstem cell marker
dc.subject.otheroncogenic signal
dc.subject.otherβ-catenin
dc.subject.othergenetic alteration
dc.subject.otherliver cancer
dc.subject.othereffectiveness
dc.subject.othersafety
dc.subject.otherHCC
dc.subject.othermolecular-targeted agent
dc.subject.otherTACE
dc.subject.othertyrosine kinase inhibitor
dc.subject.otherCD14+ cells
dc.subject.otherprogrammed death 1 ligands
dc.subject.othertranslational approaches
dc.subject.othercombination therapies
dc.subject.othertherapy resistance
dc.subject.otherpredictive markers
dc.subject.othertissue-resident memory CD8 T cells
dc.subject.otherimmune checkpoint blockade
dc.titleImmunotherapy in Hepatocellular Carcinoma
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-6690-0
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036566917
oapen.relation.isbn9783036566900
oapen.pages276
oapen.place.publicationBasel


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

https://creativecommons.org/licenses/by/4.0/
Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by/4.0/